Guyana
Tuberculosis profile
| High HIV burden |
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.13 (0.12–0.13) 16 (16–16)
Mortality (HIV+TB only) 0.03 (0.018–0.045) 3.8 (2.3–5.6)
Prevalence  (includes HIV+TB) 1 (0.49–1.8) 129 (62–220)
Incidence  (includes HIV+TB) 0.87 (0.78–0.99) 109 (97–123)
Incidence (HIV+TB only) 0.18 (0.089–0.27) 23 (11–34)
Case detection, all forms (%) 78 (69–88)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.3–3.1) 14 (4.7–22)
MDR-TB cases among notified pulmonary
TB cases
12 (7–17) 23 (8–37)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 308   23
Pulmonary, clinically diagnosed 249   38
Extrapulmonary 59   2
       
Total new and relapse 679    
Previously treated, excluding relapses 106    
Total cases notified 785    
Among 679 new and relapse cases:
22 (3%) cases aged under 15 years; male:female ratio: 2.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 (<1%) 5 (3%) 8
Laboratory-confirmed RR-/MDR-TB cases     3
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 705 (90)
HIV-positive TB patients 180 (26)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 143 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 101 (56)
HIV-positive people screened for TB 2 251  
HIV-positive people provided with IPT 192  
Treatment success rate (%)
New and relapse cases registered in 2012 65
Previously treated cases, excluding relapse, registered in 2012 50
HIV-positive TB cases, all types, registered in 2012 55
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 3.0
Culture (per 5 million population) 6.3
Drug susceptibility testing (per 5 million population) 6.3
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 2
% Funded domestically 33%
% Funded internationally 37%
% Unfunded 30%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-05 Data: www.who.int/tb/data